Author: Zhou, Yusen; Yang, Yang; Huang, Jingwei; Jiang, Shibo; Du, Lanying
Title: Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain Cord-id: eeyqh9nc Document date: 2019_1_14
ID: eeyqh9nc
Snippet: Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus that was first reported in 2012. The MERS-CoV genome encodes four major structural proteins, among which the spike (S) protein has a key role in viral infection and pathogenesis. The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics. In this review, we describe the relevant features of the MERS-CoV
Document: Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus that was first reported in 2012. The MERS-CoV genome encodes four major structural proteins, among which the spike (S) protein has a key role in viral infection and pathogenesis. The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics. In this review, we describe the relevant features of the MERS-CoV S-protein RBD, summarize recent advances in the development of MERS-CoV RBD-based vaccines and therapeutic antibodies, and illustrate potential challenges and strategies to further improve their efficacy.
Search related documents:
Co phrase search for related documents- address need and low efficiency: 1
- address need and lung disease: 1, 2, 3, 4, 5, 6
- address need and lung virus: 1
Co phrase search for related documents, hyperlinks ordered by date